AU2019310013B2 - Use of riluzole prodrugs to treat alzheimer's disease - Google Patents

Use of riluzole prodrugs to treat alzheimer's disease Download PDF

Info

Publication number
AU2019310013B2
AU2019310013B2 AU2019310013A AU2019310013A AU2019310013B2 AU 2019310013 B2 AU2019310013 B2 AU 2019310013B2 AU 2019310013 A AU2019310013 A AU 2019310013A AU 2019310013 A AU2019310013 A AU 2019310013A AU 2019310013 B2 AU2019310013 B2 AU 2019310013B2
Authority
AU
Australia
Prior art keywords
patient
riluzole prodrug
riluzole
disease
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019310013A
Other languages
English (en)
Other versions
AU2019310013A1 (en
Inventor
Robert Berman
Vladimir Coric
Irfan QURESHI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of AU2019310013A1 publication Critical patent/AU2019310013A1/en
Application granted granted Critical
Publication of AU2019310013B2 publication Critical patent/AU2019310013B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2019310013A 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease Active AU2019310013B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
US62/701,814 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2019310013A1 AU2019310013A1 (en) 2021-02-11
AU2019310013B2 true AU2019310013B2 (en) 2025-01-02

Family

ID=69181140

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019310013A Active AU2019310013B2 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Country Status (15)

Country Link
US (1) US12161633B2 (https=)
EP (1) EP3823616A4 (https=)
JP (2) JP2021530543A (https=)
KR (1) KR20210034621A (https=)
CN (1) CN112469408A (https=)
AU (1) AU2019310013B2 (https=)
BR (1) BR112021000768A2 (https=)
CA (1) CA3107215A1 (https=)
EA (1) EA202190308A1 (https=)
IL (1) IL280177B2 (https=)
MX (2) MX2021000515A (https=)
NZ (1) NZ772009A (https=)
PH (1) PH12021550043A1 (https=)
SG (1) SG11202100385YA (https=)
WO (1) WO2020023324A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230027189A (ko) * 2020-06-24 2023-02-27 바이오하벤 테라퓨틱스 리미티드 강박 장애를 치료하기 위한 조성물 및 방법
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
WO2022178425A1 (en) * 2021-02-22 2022-08-25 Yale University Targeted bifunctional degraders
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
WO2018031707A1 (en) * 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214663B2 (en) * 2000-06-14 2007-05-08 Medarex, Inc. Tripeptide prodrug compounds
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
EP3079692A4 (en) 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
WO2016085998A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
WO2017201502A1 (en) * 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
US20180037557A1 (en) * 2015-03-03 2018-02-08 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs riluzole and their method of use
WO2018031707A1 (en) * 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use

Also Published As

Publication number Publication date
CN112469408A (zh) 2021-03-09
EP3823616A1 (en) 2021-05-26
US20210290599A1 (en) 2021-09-23
SG11202100385YA (en) 2021-02-25
EA202190308A1 (ru) 2021-05-19
BR112021000768A2 (pt) 2021-05-11
NZ772009A (en) 2026-02-27
WO2020023324A1 (en) 2020-01-30
IL280177A (en) 2021-03-01
EP3823616A4 (en) 2022-05-04
IL280177B1 (en) 2024-09-01
IL280177B2 (en) 2025-01-01
MX2021000515A (es) 2021-06-08
US12161633B2 (en) 2024-12-10
KR20210034621A (ko) 2021-03-30
CA3107215A1 (en) 2020-01-30
PH12021550043A1 (en) 2021-09-20
JP2021530543A (ja) 2021-11-11
AU2019310013A1 (en) 2021-02-11
JP2025093952A (ja) 2025-06-24
MX2024010655A (es) 2024-09-11

Similar Documents

Publication Publication Date Title
AU2019310013B2 (en) Use of riluzole prodrugs to treat alzheimer's disease
US11123332B2 (en) Gaboxadol for reducing risk of suicide and rapid relief of depression
Reid et al. A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence
CN105832733A (zh) 高剂量拉喹莫德(laquinimod)用于治疗多发性硬化症的用途
Benzer et al. Case 40-2013: a 36-year-old man with agitation and paranoia
US20240082340A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
TW202339763A (zh) 用於治療多種疾病之組成物及方法
US12201618B2 (en) Use of riluzole prodrugs to treat Alzheimer's disease
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
EP4543427A1 (en) Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)
EA049330B1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
US20250375459A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
Ramos-Quiroga et al. Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults
Ibrahim et al. Influence of Early Postmortem Interval on the Detection of Hepatic Diazepam Concentrations in Male Albino Rats
CN117580576A (zh) Luvadaxistat用于治疗认知损害的用途
Gracious et al. Child and Adolescent Program of the 42nd Annual National Institute of Mental Health (NIMH) New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, Florida, June 10–13, 2002
Gurram Pharmacokinetic Evaluation of a Gastrointestinal Motility Tretment of Drug in Healthy Human Volunteers (Cinitapride)
Bhattacharyya et al. P0361-Delta-9-tetrahydrocannabinol modulates parahippocampal and ventral striatal activity during processing of verbal memory
Tariot P. 4.017 Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease
HK1252154B (zh) 左乙拉西坦的延时释放药物组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)